Challenge
IAIP is an esoteric topic understood by a narrow set of experts. Most investors searching for blood-product opportunities will not naturally encounter IAIP or recognize where it may have practical therapeutic relevance. Evidence is often fragmented across posters, abstracts, patents, and third-party pages, which makes company-level attribution weak unless the narrative is intentionally structured.